Antibody–Drug Conjugates

    Diamantis N, Banerji U. Antibody-drug conjugates–an emerging class of cancer treatment. BrJ Cancer. 2016;114(4): 362. Reprinted by permission from Springer Nature, on behalf of Cancer Research UK.
    • Antibody–drug conjugates (ADCs) are a hybrid of cytotoxic drug and specific antibody joined by a linker.
    • They provide targeted delivery of a cytotoxic agent with a reduced amount of toxicity.
    • Their efficacy depends not on a mutation in the genome, but on a suitable marker on the cell surface.
    • A successful ADC depends on a firmly attached cell surface en for the antibody to bind.
    Other topics in Molecular Targets and Pathways